Online Program Home
My Program

Abstract Details

Activity Number: 349 - Longitudinal, Spatial, and Bayesian Methods
Type: Contributed
Date/Time: Tuesday, July 31, 2018 : 10:30 AM to 12:20 PM
Sponsor: Section on Statistics in Epidemiology
Abstract #329819 Presentation
Title: Relationship Between Caffeine Intake and Autosomal Dominant Polycystic Kidney Disease Progression
Author(s): Katelyn McKenzie* and Jonathan D Mahnken and Mirelle El Ters and Vicente E Torres and Peter C Harris and Arlene B Chapman and Michal Mrug and Frederic F. Rahbari-Oskoui and Kyongtae Ty Bae and Douglas P Landsittel and William M Bennett and Alan S. L. Yu
Companies: University of Kansas Medical Center and University of Kansas Medical Center and Division of Nephrology and Hypertension, Mayo Clinic and Division of Nephrology and Hypertension, Mayo Clinic and Division of Nephrology and Hypertension, Mayo Clinic and Section of Nephrology, University of Chicago School of Medicine and Division of Nephrology, University of Alabama and Emory University School of Medicine and University of Pittsburgh School of Medicine and University of Pittsburgh School of Medicine and Legacy Good Samaritan Hospital and Division of Nephrology and Hypertension, and the Jared Grantham Kidney Institute, KUMC
Keywords: ADPKD; Caffeine; Linear Mixed Models; ESRD
Abstract:

Caffeine may accelerate progression of autosomal dominant polycystic kidney disease (ADPKD) by increasing kidney size. As ADPKD patients are advised to minimize caffeine intake, we investigated the effect of caffeine on ADPKD progression in the Consortium for Radiologic Imaging Studies of PKD, a prospective, observational cohort study. Our study included data on 239 patients over 12 years. Linear mixed models for baseline caffeine intake (any vs. none), unadjusted and adjusted for age, sex, race, hypertension, genetics and time, modeled height-adjusted total kidney volume (htTKV) and iothalamate clearance (mGFR). Cox proportional hazards models and Kaplan-Meier plots examined the effect of caffeine on time to ESRD or death. Caffeine-by-time was statistically significant when modeling ln(htTKV) (p< 0.01) indicating that caffeine consumers had an annual 0.7% faster kidney growth, but htTKV remained smaller throughout the study. Caffeine consumption was not associated with mGFR or time to ESRD or death (p>0.12). Results were similar when modeling caffeine as a continuous dose. We conclude that caffeine does not have a significant negative effect on ADPKD progression.


Authors who are presenting talks have a * after their name.

Back to the full JSM 2018 program